Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMFFIDA)

Drug Name
Garetosmab Drug Info
Indication
Disease Entry ICD 11 Status REF
Fibrodysplasia ossificans progressiva FB31.1 Phase 3 [1]
Cross-matching ID
TTD Drug ID
DMFFIDA

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Inhibin beta A chain (INHBA) TTVB30D INHBA_HUMAN Modulator [2]

References

1 ClinicalTrials.gov (NCT05394116) Phase 3 Randomized, Placebo-Controlled Study to Assess Safety, Tolerability, and Efficacy of Garetosmab in Patients With Fibrodysplasia Ossificans Progressiva. U.S.National Institutes of Health.
2 Pharmacokinetics and Pharmacodynamics of Garetosmab (Anti-Activin A): Results From a First-in-Human Phase 1 Study. J Clin Pharmacol. 2020 Nov;60(11):1424-1431.